Last reviewed · How we verify
NCT05162833
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
NA trial testing TheraNova Neuromodulation Device in Overactive Bladder in 3 participants. Completed in 8 December 2023.
8 December 2023
Quick facts
| Lead sponsor | Theranova, L.L.C. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 20 February 2022 |
| Primary completion | 8 December 2023 |
| Estimated completion | 8 December 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- TheraNova Neuromodulation Device
Conditions studied
- Overactive Bladder — all drugs for Overactive Bladder →
Sponsor
Theranova, L.L.C.
Who can join
18 and older, any sex, with Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05162833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overactive Bladder
Currently open trials in the same condition.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
- NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
- NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
- NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting
Other Theranova, L.L.C. trials
Trials by the same sponsor.
- NCT06760572 — Airway Data Collection With the Entarik Feeding Tube System · NA · recruiting
- NCT05948605 — EMPOWER AUD Pivotal Trial · NA · completed
- NCT04758247 — Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms · NA · completed
- NCT04901481 — Empower Neuromodulation System - Pilot Study for Anxiety Treatment · NA · terminated
- NCT04166045 — Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05162833 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Theranova, L.L.C.
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing